Hikma Pharmaceuticals PLC (HIK) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded.

Total Revenue Chart for Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC (HIK) revenue for FY2025 was GBP 3.3B, a 7.1% change from FY2024. Hikma Pharmaceuticals PLC's revenue grew from GBP 85.5M in 2002 to GBP 3.3B in 2025 (3816.9% over 23 years). Earnings per share grew from GBP 0.22 in 2004 to GBP 0.84 in 2022 (271.5%). Revenue compound annual growth rate: 5-year CAGR of 7.4%, 10-year CAGR of 8.8%, 20-year CAGR of 13.6%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.